MANSFIELD, Mass., Oct. 3, 2012 /PRNewswire/ -- PrimeraDx, Inc. announced today that it has been named to the FierceMedicalDevices "Fierce 15" list, designating it as one of the leading medical device and diagnostic companies of 2012. FierceMedicalDevices Editors Mark Hollmer and Damian Garde, in conjunction with Editor-in-Chief John Carroll and Executive Editor Ryan McBride, chose this year's winners based on their top management teams, notable financial backing, and promising technologies and market opportunities. PrimeraDx was chosen as one of the Fierce 15 based, in part, on its creativity and innovations in the industry.
"PrimeraDx's all-in-one ICEPlex system stands out in the burgeoning field of molecular diagnostics, and the company's recent partnerships attest to that," said Garde.
PrimeraDx recently began commercializing its ICEPlex System and is proud to be working with some of the world's leading clinical labs and pharmaceutical companies. Furthermore, the recently announced grant from the National Cancer Institute demonstrates that the ICEPlex System has differentiated capability that could have a meaningful impact on cancer diagnostics. Users can easily design very complex multi-modal assays that test for disparate target types, like SNPs, expression biomarkers, microRNAs and fusion genes.
"FierceMedicalDevices is renowned for its advanced understanding of medical device companies and the industry as a whole," said President and CEO Matt McManus, MD, Ph.D. "We are honored to have been chosen as a member of the 'Fierce 15.' It is a recognition that highlights our contributions to the clinical market and our potential to make a significant impact on patient care."
An internationally recognized e-newsletter reaching more than 34,000 medical device and diagnostic industry professionals, FierceMedicalDevices provides subscribers with a quick authoritative briefing on the day's top stories, with a special focus on clinical studies, FDA/EMEA regulations, and post-marketing. Sign up is free at http://www.fiercemedicaldevices.com/signup.
FierceMarkets, a wholly owned subsidiary of Questex Media Group, is a leader in B2B emedia, providing information and marketing services in the telecommunications, life sciences, healthcare, IT, energy, government, and finance industries through its portfolio of email newsletters, websites, webinars and live events. Every business day, FierceMarkets' wide array of publications reaches more than 1.3 million executives in more than 100 countries.
Current publications include: Telecom: FierceBroadbandWireless; FierceCable; FierceDeveloper; FierceEnterpriseCommunications; FierceIPTV; FierceMobileContent; FierceOnlineVideo; FierceTelecom; FierceWireless; FierceWireless:Europe; Healthcare: FierceEMR; FierceHealthcare; FierceHealthFinance; FierceHealthIT; FierceHealthPayer; FierceMobileHealthcare; FiercePracticeManagement; Hospital Impact; Life Sciences: FierceBiomarkers; FierceBiotech; FierceBiotechIT; FierceBiotech Research; FierceCRO; FierceDrugDelivery; FierceMedicalDevices; FiercePharma; FiercePharmaManufacturing; FierceVaccines; Energy: FierceEnergy; FierceSmartgrid; Enterprise IT: FierceBigData; FierceCIO; FierceCIO:TechWatch; FierceContentManagement; FierceMobileIT; Finance: FierceComplianceIT; FierceFinance; FierceFinanceIT; Government: FierceGovernment; FierceGovernmentIT; FierceHomelandSecurity; and FierceMobileGovernment.
PrimeraDx is a molecular diagnostics company that has developed and is commercializing a novel, game-changing clinical platform which combines PCR with capillary electrophoresis. The result of combining these two well-known technologies into a bench-top instrument is the ability to deliver highly multiplexed and quantitative answers to the clinic. The company is pursuing a two-pronged strategy to sell the system in an Open Platform Mode to clinical labs and to independently develop high-value molecular diagnostic products. Users can easily design very complex multi-modal assays that test for disparate target types, like SNPs, expression biomarkers, microRNAs and fusion genes. PrimeraDx's technology represents the next generation of quantitative, multiplex PCR. The Company is backed by a strong group of experienced venture-capital investors, including Abingworth, InterWest Partners, CHL Medical Partners, and Malaysian Technology Development Corporation. The Company's website is: www.primeradx.com or www.multiplexpcr.com.